Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Koldingsnes, W.
Right arrow Articles by Husby, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koldingsnes, W.
Right arrow Articles by Husby, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The British Journal of Rheumatology, Vol 37, 659-664, Copyright © 1998 by British Society for Rheumatology

ORIGINAL PAPERS

Wegener's granulomatosis: long-term follow-up of patients treated with pulse cyclophosphamide

W Koldingsnes, JT Gran, R Omdal and G Husby
Department of Rheumatology, University Hospital, Tromso, Norway.

Treatment with daily oral cyclophosphamide (CY) has improved survival in Wegener's granulomatosis (WG), but is associated with severe and potentially lethal adverse effects. Less toxic treatment regimens, such as pulse CY, have been used, but the effect has been questioned. We have treated 11 patients with WG with pulse CY (15 mg/kg initially every second week, gradually increasing the pulse interval). After 4.5 yr follow-up and a total of 501 pulses of CY, one patient died and eight patients (73%) were in complete remission. Remission was induced in 91% of the patients after a median period of 3.5 months and relapses were seen in 60%. With the same treatment protocol, a new complete remission was induced in 75% of those relapsing. Except for one patient who died, no patient developed end-stage renal failure. Haemorrhagic cystitis was not observed and no malignancies recorded. Severe infections were seen in 36%, but none caused by Pneumocystis carinii. Nausea was the most frequent side-effect, seen in 64% of the patients. We conclude that treatment with pulse CY every second week is safe and effective in inducing remission and treating relapses in WG. The relapse rate seems to be higher than with low-dose oral CY, but the cumulative dose of CY is less.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
X. Bosch, A. Guilabert, G. Espinosa, and E. Mirapeix
Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review
JAMA, August 8, 2007; 298(6): 655 - 669.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
S.E. Lane, R.A. Watts, L. Shepstone, and D.G.I. Scott
Primary systemic vasculitis: clinical features and mortality
QJM, February 1, 2005; 98(2): 97 - 111.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
W. Koldingsnes and H. Nossent
Predictors of survival and organ damage in Wegener's granulomatosis
Rheumatology, May 1, 2002; 41(5): 572 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
K. d. Groot, D. Adu, and C. O. S. Savage
The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review
Nephrol. Dial. Transplant., October 1, 2001; 16(10): 2018 - 2027.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
T TAKAOKA, Y MATSUKAWA, Y TOMITA, N KITAMURA, T YAMAZAKI, J TAKEUCHI, S NISHINARITA, U SAWADA, and T HORIE
Development of erythroleukaemia after myelodysplastic syndrome in a patient with Wegener's granulomatosis
Ann Rheum Dis, September 1, 2001; 60(9): 899 - 900.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.